The Evolution of Immunotherapy Against Tumors: An Historical Approach summarizes the literature concerning the development of the theory of immune surveillance against tumors. It discusses the evidence for and against this theory, along with the concept of immunoediting. Finally, current approaches in anti-tumor immunotherapy will be analyzed. The immune system plays a major role in the surveillance against tumors. To avoid attack from the immune system, tumor cells develop different strategies to escape immune surveillance. Evidence of immune surveillance comes from both animal models and clinical observations. Mice with a wide variety of immunodeficiencies have a high rate of tumor incidence and are more susceptible to transplanted or chemical carcinogen-induced tumors. Immunosuppressed patients have a high incidence of tumors. However, many patients develop cancer even in the presence of an apparently normal immune system. This indicates that tumor cells can escape immune surveillance.
1. The Evolution of Immunotherapy Against Tumors - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page ii 4. Table of Contents - p. Page iii 5. Copyright - p. Page iv 6. Preface - p. Page v 7. List of Illustrations - p. Page vi 8. List of Tables - p. Page vii 9. 1 : Historical background - p. Page vii 10. 2 : First evidence - p. Page 26 11. 3 : Bacillus Calmette–Guerin - p. Page 29 12. 4 : Immunosurveillance against tumors - p. Page 32 13. 5 : Immunoediting - p. Page 36 14. 6 : Inflammation and tumors - p. Page 39 15. 7 : Therapeutic implications - p. Page 77 16. 8 : Cytokine therapies - p. Page 80 17. 9 : Adoptive T cell therapy - p. Page 87 18. 10 : Tumors express specific antigens - p. Page 87 19. 11 : Monoclonal antibodies - p. Page 97 20. 12 : Immunosuppressive effects of VEGF - p. Page 113 21. 13 : Immunomodulatory effects of angiopoietin, platelet derived growth factor, and hepatocyte growth factor - p. Page 116 22. 14 : Oncolytic virus therapy - p. Page 120 23. 15 : Cancer vaccines - p. Page 123 24. 16 : Engineering of T cells and CAR-T therapy - p. Page 130 25. 17 : Immune checkpoint inhibitors - p. Page 134 26. 18 : Co-applying anti-angiogenic and immune checkpoint inhibitors - p. Page 140 27. 19 : Combination therapies - p. Page 143 28. 20 : Conclusions - p. Page 143 29. References - p. Page 150 30. Index - p. Page 150
The Evolution of Immunotherapy Against Tumors: An Historical Approach summarizes the literature concerning the development of the theory of immune surveillance against tumors. It discusses the evidence for and against this theory, along with the concept of immunoediting. Finally, current approaches in anti-tumor immunotherapy will be analyzed. The immune system plays a major role in the surveillance against tumors. To avoid attack from the immune system, tumor cells develop different strategies to escape immune surveillance. Evidence of immune surveillance comes from both animal models and clinical observations. Mice with a wide variety of immunodeficiencies have a high rate of tumor incidence and are more susceptible to transplanted or chemical carcinogen-induced tumors. Immunosuppressed patients have a high incidence of tumors. However, many patients develop cancer even in the presence of an apparently normal immune system. This indicates that tumor cells can escape immune surveillance.
1. The Evolution of Immunotherapy Against Tumors - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page ii 4. Table of Contents - p. Page iii 5. Copyright - p. Page iv 6. Preface - p. Page v 7. List of Illustrations - p. Page vi 8. List of Tables - p. Page vii 9. 1 : Historical background - p. Page vii 10. 2 : First evidence - p. Page 26 11. 3 : Bacillus Calmette–Guerin - p. Page 29 12. 4 : Immunosurveillance against tumors - p. Page 32 13. 5 : Immunoediting - p. Page 36 14. 6 : Inflammation and tumors - p. Page 39 15. 7 : Therapeutic implications - p. Page 77 16. 8 : Cytokine therapies - p. Page 80 17. 9 : Adoptive T cell therapy - p. Page 87 18. 10 : Tumors express specific antigens - p. Page 87 19. 11 : Monoclonal antibodies - p. Page 97 20. 12 : Immunosuppressive effects of VEGF - p. Page 113 21. 13 : Immunomodulatory effects of angiopoietin, platelet derived growth factor, and hepatocyte growth factor - p. Page 116 22. 14 : Oncolytic virus therapy - p. Page 120 23. 15 : Cancer vaccines - p. Page 123 24. 16 : Engineering of T cells and CAR-T therapy - p. Page 130 25. 17 : Immune checkpoint inhibitors - p. Page 134 26. 18 : Co-applying anti-angiogenic and immune checkpoint inhibitors - p. Page 140 27. 19 : Combination therapies - p. Page 143 28. 20 : Conclusions - p. Page 143 29. References - p. Page 150 30. Index - p. Page 150
